These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 16167063)
21. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors. Brieger A; Boehrer S; Schaaf S; Nowak D; Ruthardt M; Kim SZ; Atadja P; Hoelzer D; Mitrou PS; Weidmann E; Chow KU Biochem Pharmacol; 2004 Jul; 68(1):85-93. PubMed ID: 15183120 [TBL] [Abstract][Full Text] [Related]
22. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Fulda S; Meyer E; Debatin KM Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673 [TBL] [Abstract][Full Text] [Related]
23. Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins. Fandy TE; Srivastava RK Cancer Chemother Pharmacol; 2006 Oct; 58(4):471-7. PubMed ID: 16435155 [TBL] [Abstract][Full Text] [Related]
24. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP; Zisman A; Bonavida B Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140 [TBL] [Abstract][Full Text] [Related]
26. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754 [TBL] [Abstract][Full Text] [Related]
27. Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist. Griffith TS; Kucaba TA; O'Donnell MA; Burns J; Benetatos C; McKinlay MA; Condon S; Chunduru S Apoptosis; 2011 Jan; 16(1):13-26. PubMed ID: 20734142 [TBL] [Abstract][Full Text] [Related]
28. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Kang J; Bu J; Hao Y; Chen F Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917 [TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660 [TBL] [Abstract][Full Text] [Related]
30. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma. Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304 [TBL] [Abstract][Full Text] [Related]
31. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289 [TBL] [Abstract][Full Text] [Related]
32. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094 [TBL] [Abstract][Full Text] [Related]
33. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Kazhdan I; Marciniak RA Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201 [TBL] [Abstract][Full Text] [Related]
34. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Mizutani Y; Yoshida O; Miki T; Bonavida B Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639 [TBL] [Abstract][Full Text] [Related]
35. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154 [TBL] [Abstract][Full Text] [Related]
36. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Nguyen T; Zhang XD; Hersey P Clin Cancer Res; 2001 Mar; 7(3 Suppl):966s-973s. PubMed ID: 11300498 [TBL] [Abstract][Full Text] [Related]
37. Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Horak P; Pils D; Kaider A; Pinter A; Elandt K; Sax C; Zielinski CC; Horvat R; Zeillinger R; Reinthaller A; Krainer M Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8585-91. PubMed ID: 16361541 [TBL] [Abstract][Full Text] [Related]
38. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671 [TBL] [Abstract][Full Text] [Related]
39. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850 [TBL] [Abstract][Full Text] [Related]
40. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]